natgillin/translations-raw huggingface dataset:
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and preexisting major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. 
V PROaktivni kardiovaskularni študiji izida je bilo 5238 bolnikov s sladkorno boleznijo tipa 2 in že prej obstoječimi težjimi makrovaskularnimi boleznimi naključno dodatno zdravljenih s pioglitazonom ali placebom k že obstoječemu antidiabetičnemu in kardiovaskularnemu zdravljenju, v trajanju do 3,5 let.
It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes. 
Zato je priporočeno, da pri bolnikih, zdravljenih s pioglitazonom, redno spremljate vrednosti jetrnih encimov.
Blood and lymphatic system disorders anaemia common 
Bolezni krvi in limfatič-nega sistema anemija
Patients should be observed for signs and symptoms of heart failure, weight gain and oedema when pioglitazone is used in combination with insulin. 
Bolnike je treba opazovati zaradi znakov in simptomov srčnega popuščanja, povečanja telesne mase in edema, ko se pioglitazon uporablja v kombinaciji z insulinom.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. 
Študije pri človeku ne kažejo nobenih indukcij poglavitnih inducibilnih citokromov P450, 1A, 2C8/9
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone. 
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (hemoglobin 3-4 % in hematokrit 3,6-4,1 % relativna znižanja), in v manjšem obsegu pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (hemoglobin 1-2 % in hematokrit 1-3,2 % relativna znižanja).
In comparator groups addition of sulphonylurea to metformin resulted in a mean weight gain of 1.3 kg and addition of metformin to a sulphonylurea a mean weight loss of 1.0 kg. 
V primerjalnih skupinah je dodatek sulfonilsečnine metforminu povzročil povprečno povečanje telesne mase za 1,3 kg in dodatek metformina sulfonilsečnini povprečno zmanjšanje telesne mase za 1,0 kg.
The dose may be increased in increments up to 45 mg once daily. 
Odmerek lahko postopoma zvišujemo do 45 mg enkrat dnevno.
Visceral fat was significantly decreased, while there was an increase in extra-abdominal fat mass. 
Količina visceralnega maščevja se je značilno zmanjšala, medtem ko se je masa ekstraabdominalnega maščevja zvečala.
In vitro studies have shown no inhibition of any subtype of cytochrome P450. 
Študije in vitro niso pokazale inhibicije kakega podtipa citokroma P450.
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 ml/min) (see section 5.2). 
Pri bolnikih z okvarjenim delovanjem ledvic (očistek kreatinina > 4 ml/min) odmerka ni treba prilagajati (glejte poglavje 5.2).
Investigations weight increased6 common common common common common blood creatine phospho-kinase increased common increased lactic dehydro-genase uncommon alanine aminotransferase increased7 
povišana vrednost keratin fosfokinaze v krvi povišana vrednost laktatne dehidro-genaze občasni povišana vrednost alanin aminotransferaze7
However, the incidences of oedema, weight gain and heart failure were increased. 
Vendar je bila povečana incidenca edemov, pridobivanja telesne mase in srčnih odpovedi.
Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure. 
Zastajanje tekočine in srčno popuščanje Pioglitazon lahko povzroči zastajanje tekočine, to pa lahko poslabša ali pospeši srčno popuščanje.
- if you have cysts on your ovaries (polycystic ovary syndrome). 
- če imate ciste na jajčnikih (sindrom policističnih jajčnikov).
In combination trials pioglitazone added to metformin resulted in mean weight increase over one year of 1.5 kg and added to a sulphonylurea of 2.8 kg. 
V preskušanjih kombiniranega zdravljenja je pioglitazon, dodan metforminu, povzročil povprečno povečanje telesne mase v enem letu za 1,5 kg oziroma, dodan sulfonilsečnini, za 2,8 kg.
Contents of the pack and other information What Pioglitazone Teva contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Pioglitazon Teva
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. 
20-tedenski študiji je pioglitazon znižal raven trigliceridov na tešče, pa tudi hipertrigliceridemijo po obroku prek učinkovanja na absorbirane in v jetrih sintetizirane trigliceride.
Reproductive system and breast disorders erectile dysfunction common 
Motnje reproduk-cije in dojk erektilna disfunkcija
- The active substance is pioglitazone. 
- Zdravilna učinkovina je pioglitazon.
However if you miss a dose, just carry on with the next dose as normal. 
nadaljujte z naslednjim odmerkom kot sicer.
Talk to your doctor or pharmacist before taking Pioglitazone Teva (also see section 4) 
Pred začtkom jemanja zdravila Pioglitazon Teva se posvetujte z zdravnikom ali farmacevtom (glejte tudi poglavje 4):
Liver enzymes should be checked prior to the initiation of therapy with pioglitazone in all patients. 
Jetrne encime je treba pri vseh bolnikih kontrolirati pred uvedbo zdravljenja s pioglitazonom.
Eye disorders visual disturbance2 
Očesne bolezni motnje vida2
How to store Pioglitazone Teva Contents of the pack and other information 
Shranjevanje zdravila Pioglitazon Teva Vsebina pakiranja in dodatne informacije
4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration. 
4 Opravljena je bila skupna analiza neželenih učinkov zlomov kosti iz randomiziranih, s primerjalnim zdravilom nadzorovanih, dvojno slepih kliničnih preskušanj pri več kot 8100 bolnikov v skupini zdravljeni s pioglitazonom in 7400 v skupini zdravljeni s primerjalnim zdravilom, ki so trajale do 3,5 let.
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. 
Zlome so opazili pri 2,6 % žensk, ki so jemale pioglitazon v primerjavi s 1,7 % žensk, zdravljenih s primerjalnim zdravilom.
There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. 
(4 % relativno znižanje) in hematokrita (4,1 % relativno znižanje), skladno s hemodilucijo.
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥65 years compared to 4.0% in patients less than 65 years. 
Pri bolnikih, ki so se zdravili samo z insulinom, brez pioglitazona, je odstotek srčnega popuščanja pri bolnikih, starih 65 let in starejših, znašal 8,2 %, pri bolnikih, mlajših od 65 let, pa 4,0 %.
very common fatigue uncommon 
zelo pogosti utrujenost občasni
- diabetic ketoacidosis - current bladder cancer or a history of bladder cancer - uninvestigated macroscopic haematuria 
- z rakom mehurja ali rakom mehurja v anamnezi - z neraziskano makroskopsko hematurijo
In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL cholesterol levels, compared with placebo, metformin or gliclazide. 
V kliničnih preskušanjih, ki so trajala do dve leti, je pioglitazon znižal skupne plazemske trigliceride in proste maščobne kisline ter povišal ravni HDL holesterola v primerjavi s placebom, metforminom ali gliklazidom.
If you stop taking Pioglitazone Teva 
Če ste prenehali jemati zdravilo Pioglitazon Teva
7 In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. 
7V kliničnih preskušanjih pioglitazona je bila incidenca povišanih vrednosti ALT, višjih kot trikratna zgornja meja normalnih vrednosti, enaka kot pri placebu, vendar nižja kot v primerjalnih skupinah z metforminom ali sulfonilsečnino.
Skin and subcutaneous tissue disorders sweating uncommon 
Bolezni kože in podkožja znojenje občasni
The usual starting dose is one tablet of 15 mg or of 30 mg of pioglitazone to be taken once daily. 
Običajni začetni odmerek je ena 15-miligramska ali 30-miligramska tableta pioglitazona enkrat dnevno.
Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
O srčnem popuščanju so poročali tudi pri tržni uporabi pioglitazona, in sicer pogosteje pri uporabi pioglitazona v kombinaciji z insulinom ali pri bolnikih z anamnezo srčnega popuščanja.
When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy. 
koncentracije in vezavo na beljakovine, je delež učinkovitosti pioglitazona in presnovka M-III enak.
Patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued (see section 4.6). 
Zato se morajo tveganja za zanositev zavedati, in če bolnica želi zanositi ali zanosi, je treba zdravljenje prekiniti
6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year. 
6V kontroliranih preskušanjih s primerjalnim zdravilom je bilo povprečno povečanje telesne mase pri pioglitazonu, dajanemu kot monoterapija, 2-3 kg v enem letu.
Frequency of adverse reactions of pioglitazone by treatment regimen 
Neželeni učinki Pogostnost neželenih učinkov pioglitazona glede na režim zdravljenja
Therapy with pioglitazone should not be initiated in patients with increased baseline liver enzyme levels (ALT > 2.5 X upper limit of normal) or with any other evidence of liver disease. 
Pri bolnikih s povišanimi izhodiščnimi ravnmi jetrnih encimov (ALT > 2,5-kratna zgornja meja normalnih vrednosti) ali s kakršnimikoli drugimi znaki jetrne bolezni zdravljenja s pioglitazonom ne smemo začeti.
Pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below: 
Pioglitazon je indiciran za zdravljenje sladkorne bolezni tipa 2:
Infections and infestations upper respiratory tract infection common common common common common bronchitis common sinusitis uncommon uncommon uncommon uncommon uncommon 
Infekcijske in parazitske bolezni okužba zgornjih dihal bronhitis sinusitis občasni občasni občasni občasni občasni
What Pioglitazone Teva looks like and contents of the pack 
Izgled zdravila Pioglitazon Teva in vsebina pakiranja
Heart failure has been experienced commonly (may affect up to 1 in 10 people) in patients taking pioglitazone in combination with insulin. 
Odpoved srca je bila pogosto (pojavijo se lahko pri največ 1 od 10 bolnikov) ugotovljena pri pacientih, ki so jemali pioglitazon v kombinaciji z insulinom.
nausea or vomiting). 
zlome in srčno popuščanje).
In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys. 
V toksikoloških študijah so se po večkratnem odmerjanju mišim, podganam, psom in opicam stalno pojavljali povečanje volumna plazme s hemodilucijo, anemija in reverzibilna ekscentrična hipertrofija srca.
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
B. POGOJI ALI OMEJITVE GLEDE OSKERBE IN UPORABE
Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience. 
V postmarketinških izkušnjah so se pojavljali redki primeri povišanih vrednosti jetrnih encimov in hepatocelularne disfunkcije.
Your doctor will ask you to have blood tests periodically during treatment with Pioglitazone Teva. 
Zdravnik vas bo v času zdravljenja z zdravilom Pioglitazon Teva naročil na redne preiskave krvi.
The other side effects that have been experienced by some patients when pioglitazone is taken with other antidiabetic medicines are: 
Pri nekaterih bolnikih, ki so jemali pioglitazon skupaj z drugimi antidiabetičnimi zdravili, so se pojavili naslednji dodatni neželeni učinki:
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. 
V 3,5 letni PROactive študiji kardiovaskualarnega tveganja, je 44/870 (5,1 %; 1,0 zlom na 100 bolniških let) žensk, zdravljenih s pioglitazonom imelo zlome, v primerjavi s 23/905 (2,5 %;
Pioglitazone was associated with significant weight gain. 
Pioglitazon je bil povezan z značilnim povečanjem telesne mase.
The risk of fractures should be considered in the long term care of patients treated with pioglitazone (see section 4.8). 
Pri dolgoročnem zdravljenju bolnikov s pioglitazonom, je potrebno upoštevati tveganje za zlome (glejte poglavje 4.8).
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. 
kot trojno peroralno zdravljenje v kombinaciji z metforminom in sulfonilsečnino pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub dvojnemu peroralnemu zdravljenju.
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. 
Poročali so, da sočasno dajanje pioglitazona z rifampicinom (induktor citokroma P450 2C8) povzroči 54 % zmanjšanje AUC pioglitazona.
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking pioglitazone. 
Rak mehurja se lahko pojavi občasno (pojavijo se lahko pri največ 1 od 10 bolnikov) pri bolnikih, ki jemljejo pioglitazon.
Cardiac disorders heart failure3 
Srčne bolezni srčno popuščanje3
How to take Pioglitazone Teva 
Kako jemati zdravilo Pioglitazon Teva
Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk. 
zdravljenih s pioglitazonom, čeprav pri vseh študijah povečanje tveganja ni bilo statistično signifikantno.
This leaflet was last revised in {MM/YYYY}. 
Navodilo je bilo nazadnje revidirano mesec LLLL Drugi viri informacij
Respiratory, thoracic and mediastinal disorders dyspnoea common 
Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
S trga so poročali o primerih srčnega popuščanja, ko so pioglitazon uporabljali v kombinaciji z insulinom ali pri bolnikih s srčnim popuščanjem v anamnezi.
Take Pioglitazone Teva daily as prescribed. 
Če ste pozabili vzeti zdravilo Pioglitazon Teva Zdravilo Pioglitazon Teva jemljite vsak dan, kakor vam je predpisano.
If you experience this side effect, talk to your doctor as soon as possible. 
Če ste opazili ta neželeni učinek, se posvetujte s svojim zdravnikom kakor hitro mogoče.
Hypoglycaemia may occur in combination with sulphonylureas or insulin. 
V kombinaciji s sulfonilsečninami ali insulinom se lahko pojavi hipoglikemija.
Pioglitazone Teva should be used every day to work properly. 
Za pravilno delovanje je potrebno zdravilo Pioglitazon Teva jemanti vsak dan.
However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these. 
- gemfibrozil (uporablja se za zniževanje holesterola) - rifampicin (uporablja se za zdravljenje tuberkuloze in drugih okužb)
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDLcholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels. 
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom, z majhnimi,
Allergic reactions have been reported (frequency cannot be estimated from the available data) in patients taking pioglitazone. 
Pri bolnikih, ki jemljejo zdravilo pioglitazon, so poročali o alergijskih reakcijah (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. 
Če bolnik razvije simptome, ki kažejo na moteno delovanje jeter, kar lahko vključuje nepojasnjeno slabost, bruhanje,
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription. 
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z
Metabolism and nutrition disorders hypo-glycaemia uncommon very common 
Presnovne in prehranske motnje hipo-glikemija občasni zelo pogosti povečan apetit občasni
A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). 
Opazili so višjo stopnjo zlomov pri ženskah, ki so jemale pioglitazon (2,6 %) v primerjavi s primerjalnim zdravilom (1,7 %).
No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%). 
Pri moških, zdravljenih s pioglitazonom, niso opazili povečane stopnje zlomov (1,3 %) v primerjavi s primerjalnim zdravilom (1,5 %).
Your weight should be checked at regular intervals; if your weight increases, inform your doctor. 
Če se vam telesna masa znatno poveča, o tem obvestite svojega zdravnika.
The other side effects that have been experienced by some patients taking pioglitazone are: 
Pri nekaterih bolnikih, ki so jemali pioglitazon, so se pojavili drugi neželeni učinki:
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. 
Pri tiazolidindionih, vključno s pioglitazonom, so v postmarketinških poročilih poročali o novonastalih ali poslabšanjih diabetičnega makularnega edema z zmanjšanjem vidne ostrine.
It is an anti-diabetic medicine used to treat type 2 (noninsulin dependent) diabetes mellitus in adults, when metformin is not suitable or has failed to work adequately. 
Je antidiabetično zdravilo za zdravljenje sladkorne bolezni tipa 2 (od insulina neodvisne sladkorne bolezni) pri odraslih.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years. 
V skupni analizi neželenih učinkov zlomov kosti iz randomiziranih, nadzorovanih, dvojno slepih kliničnih preskušanj pri več kot 8100 s pioglitazonom in 7400 s primerjalnim zdravilom zdravljenimi bolniki, ki so se zdravili do 3,5 let, so opazili povečano incidenco zlomov kosti pri ženskah.
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin common appetite increased uncommon 
Kombinacija z metforminom s sulfonil sečnino z metforminom in sulfonil sečnino z inzulinom sistema in vezivnega tkiva zlomi kosti4
Weight gain 
- povečan apetit
Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible. 
Prav tako se kakor hitro mogoče posvetujte s svojim zdravnikom, če ste imeli zamegljen vid že prej, pa se vam je stanje poslabšalo.
Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin). 
Pri uporabi pioglitazona in sočasnim dajanjem z zaviralci (npr. gemfibrozil) ali induktorji (npr. rifampicin) citokroma P450 2C8 je potrebna previdnost.
Pioglitazone should be discontinued if any deterioration in cardiac status occurs. 
Če se pojavi kakršnokoli poslabšanje srčnega statusa, je treba zdravljenje s pioglitazonom ukiniti.
Teл. 
ČET
No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). 
Pri moških, zdravljenih s pioglitazonom, niso opazili povečane stopnje zlomov (1,7 %) v primerjavi s primerjalnim zdravilom (2,1 %).
The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat. 
predstavljalo mehansko osnovo opaženega tumorogenega odgovora pri samcih podgan.
Nervous system disorders hypo-aesthesia common common common common common headache common uncommon dizziness common insomnia uncommon uncommon uncommon uncommon uncommon 
Bolezni živčevja hipestezija glavobol občasni omotica nespečnost občasni občasni občasni občasni občasni
A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA1c ≥ 8.0% after the first six months of therapy). 
Za oceno časa do neuspeha zdravljenja (definirano kot pojav HbA1c ≥ 8,0 % po prvih šest mesecih zdravljenja) so klinično preskušanje pioglitazona v primerjavi z gliklazidom kot monoterapiji podaljšali na dve leti.
Foetal growth restriction was apparent in animal studies with pioglitazone. 
V študijah s pioglitazonom na živalih so opažali zastoj v rasti plodu.
common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) - sweating - tiredness - increased appetite 
- vetroviobčasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - sladkor v urinu, beljakovine v urinu - povišanje vrednosti encimov
- Pioglitazone Teva 30 mg tablets are white to off white, round, convex with the number ‘30' on one side and ‘TEVA' on the other side. 
- Tablete zdravila Pioglitazon Teva 30 mg so bele do umazano bele barve, okrogle, izbočene, z oznako »30« na eni strani in »TEVA« na drugi strani.
Neoplasms benign, malignant and unspecified (including cysts and polyps) 
Benigne, maligne in neopredeljene novotvorbe
Blurred vision due to swelling (or fluid) at the back of the eye (frequency cannot be estimated from the available data) has also been reported in patients taking pioglitazone. 
Pacienti, ki so jemali pioglitazon, so poročali tudi o zamegljenem vidu zaradi otekanja (ali tekočine) očesnega ozadja (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Renal and urinary disorders haematuria common glycosuria uncommon proteinuria uncommon 
Bolezni sečil hematurija glikozurija občasni proteinurija občasni
Broken bones have been reported commonly (may affect up to 1 in 10 people) in female patients taking pioglitazone and have also been reported in male patients (frequency cannot be estimated from the available data) taking pioglitazone. 
O zlomih so poročali tudi pri bolnikih, ki so se zdravili s pioglitazonom (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use. 
Opazovano povečano tveganje za zlom pri ženskah v tej skupini podatkov na pioglitazonu je torej